Synopsis: Windlas Biotech Ltd reported a steady Q4 FY26 performance with healthy year-on-year revenue growth and stable profitability. The company also announced a dividend of Rs. 6.30 per equity share for FY26. Growth in pharmaceutical manufacturing demand, expanding CDMO opportunities, and improving domestic healthcare consumption continued to support the company’s operational momentum during the quarter.
Windlas Biotech Limited, one of India’s prominent pharmaceutical formulations manufacturers and CDMO players, announced its Q4 FY26 results along with a dividend recommendation for shareholders. The company continues to strengthen its presence across contract manufacturing, trade generics, and export-focused pharmaceutical businesses.
Windlas Biotech currently commands a market capitalization of Rs. 1,633 crore, with the stock trading around Rs. 779 down by 0.50% compared to its previous close of Rs. 782. The company has maintained healthy return ratios with ROCE at 15.9 percent and ROE at 12.2 percent. The stock touched a 52-week high of Rs. 1,098 and a low of Rs. 697.
Windlas Biotech reported revenue of Rs. 238 crore in Q4 FY26, compared to Rs. 233 crore in Q3 FY26 and Rs. 203 crore in Q4 FY25. Revenue grew by around 2 percent QoQ and nearly 17 percent YoY, supported by steady demand across pharmaceutical manufacturing and CDMO operations.
Operating profit stood at Rs. 25 crore during Q4 FY26 as against Rs. 24 crore in Q3 FY26 and Rs. 26 crore in Q4 FY25. Operating profit improved by about 4 percent sequentially, while margins moderated slightly on a yearly basis with OPM standing at 11 percent.
Profit before tax came in at Rs. 20 crore in Q4 FY26 compared to Rs. 20 crore in Q3 FY26 and Rs. 21 crore in Q4 FY25, remaining broadly stable across periods. Net profit stood at Rs. 16 crore during Q4 FY26, compared to Rs. 15 crore in Q3 FY26 and Rs. 16 crore in Q4 FY25. Net profit increased by nearly 7 percent QoQ while remaining stable on a YoY basis.
The Board of Directors recommended a dividend of Rs. 6.30 per equity share of face value Rs. 5 each for FY26, representing a 126 percent dividend payout. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM) and will be credited within 30 days from the conclusion of the meeting.
Industry Outlook
India’s pharmaceutical market is expected to surpass Rs. 11 lakh crore by 2030, supported by rising healthcare expenditure, increasing chronic disease prevalence, and strong export demand. Government initiatives such as the PLI scheme and API manufacturing incentives continue to strengthen domestic pharmaceutical manufacturing capabilities.
India also remains one of the world’s largest suppliers of generic medicines, with over 2,000 WHO-GMP approved facilities and a strong presence in regulated markets. Rising outsourcing demand and growing CDMO opportunities are expected to support long-term growth for companies like Windlas Biotech.
Windlas Biotech delivered a stable Q4 FY26 performance with steady revenue growth and resilient profitability despite margin pressure. The company’s healthy dividend payout, expanding manufacturing capabilities, and strong positioning in the pharmaceutical CDMO segment continue to support its long-term growth outlook amid rising domestic and global healthcare demand.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
